A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma-Reference-Cited by-同舟云学术

A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma

Published:2022 Issue:23 Volume:10 Page:6740-6748
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Chen Xinjie¹,Cen Lanqi¹,Liu Qin²,Chu Yanhong²,Feng Xiaoyu³,Ke Yaohua²,Zhang Zhe³,Dai Hengheng¹,Huang Shuling⁴,Liu Baorui¹²³^ORCID,Qian Xiaoping²^ORCID

Affiliation:

1. The Comprehensive Cancer Center, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, China

2. The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China

3. The Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China

4. Department of Gastroenterology, Drum Tower Hospital, Affiliated to Medical School of Nanjing University, Nanjing, China

Abstract

A dual-adjuvant neoantigen nanoparticle loaded with imiquimod and magnesium (R837-Pep@HM NP) can enhance the anti-tumor immune response. The dendritic cells activated and presented neoantigens, which in turn activated T cells and killed tumor cells.

Funder

Key Project of Science and Technology Development of Nanjing Medicine

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2022/BM/D2BM01340A

Reference50 articles.

1. An immunogenic personal neoantigen vaccine for patients with melanoma

2. Dendritic Cells